Investment
Features
FeesSafety
Academy
More
Pluang+

Bitwise to liquidate its Dogecoin ETF, ending trading on Oct 14 with cash payouts on Oct 22.

Market News
11 Sep 2026
Crypto news
View Source
Bearish
Bitwise to liquidate its Dogecoin ETF, ending trading on Oct 14 with cash payouts on Oct 22.

Bitwise announced it will liquidate its Dogecoin ETF (BWOW), ceasing trading on the NYSE Arca on October 14, 2026. Shareholders will receive cash based on the fund's net asset value as of October 21, with payouts scheduled for October 22. The closure comes less than a year after the fund's launch and is part of Bitwise's strategy to optimize its product lineup. The fund's liquidation may trigger taxable events for investors, and Bitwise will stop creating new shares before trading ends. Despite the closure, Bitwise continues to offer a broad range of crypto investment products.

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
1 hour ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
3 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
3 hours ago
Anteris Technologies gains German approval to expand PARADIGM heart valve trial in Europe.

Anteris Technologies gains German approval to expand PARADIGM heart valve trial in Europe.

Anteris Technologies has received full regulatory clearance from Germany to expand its PARADIGM trial for the DurAVR transcatheter heart valve, targeting patients with severe calcific aortic stenosis. This approval allows the company to recruit patie...

Market News
Bullish
4 hours ago
Nvidia commits nearly $10B to boost Europe's AI, backing four German startups and partnering with German industry.

Nvidia commits nearly $10B to boost Europe's AI, backing four German startups and partnering with German industry.

Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App